Asian patients exhibited higher overall survival compared to other races (adjusted HR: 0.88, 95% CI: 0.82-0.95).Conclusions:Use of immunotherapy for stage IV NSCLC is substantially lower among Blacks and other minority groups compared to Whites, indicating racial disparities in access to novel lung...
both in PD-L1-positive as well as -negative patients. And so if you have lung cancer and half of the patients are PD-L1-negative, you want to do more for those
Stereotactic ablative radiotherapy (SABR) is standard-of-care for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC), however the risk of systemic recurrences remains high. Here the authors report the results of a phase I study testing the addition of atezolizumab (...
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial While the emergence of immune checkpoint inhibitors has improved cancer patient outcomes, efficacy in high-grade serous ovarian cancer (HGSOC) is limited. Here, the authors report a phase 2 ...
LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Ann Oncol. 2023;34(Suppl 2):S1297-S1298. doi:10.1016/j.annonc.2023.10.052Google ScholarCrossref 12. Jiang J, Wang Y, Gao Y, et al. ...
It also highlighted TMB as a potential predictive biomarker for the efficacy of dual ICI combination therapy and evaluated its threshold value. CheckMate 227 [81], an open-label Phase III clinical trial, classified patients with stage IV or recurrent NSCLC based on PD-L1 expression (≥ 1% ...
Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease 5.3.1.2 Immunotherapy Three immunotherapy (IO) drugs are currently licensed for use in patients with metastatic melanoma; the anti-CTLA4 monoclonal antibody (mAb) ipilimumab and the two anti-PD1 mAbs, nivolumab and ...
+ T-cell inactivation by blocking specific inhibitory receptors on the T-cell surface, have produced remarkable improvements in long-term survival for patients with aggressive cancers including metastatic melanoma and non-small cell lung cancer (NSCLC) not seen with traditional chemotherapies [1–4]....
Treatment for patients with unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based chemoradiation changed significantly with the FDA approval of durvalumab in February 2018. The approval was based on findings from the double-blind, placebo controlled, international...
The authors previously reported the primary outcomes of a randomized phase II trial comparing neoadjuvant durvalumab (anti-PD-L1) alone or in combination with stereotactic radiotherapy in patients with early-stage NSCLC. Here, the authors report the secondary outcomes of the trial and post hoc analys...